Depomed (DEPO) Tops Q2 EPS by 3c, Updates Guidance
Tweet
Share
E-mail
Get Alerts DEPO Hot Sheet
Price: $7.30 --0%
Financial Fact:
Research and development expense: 10.41M
Today's EPS Names:
ANAB, ANIX, MNY, More
Financial Fact:
Research and development expense: 10.41M
Today's EPS Names:
ANAB, ANIX, MNY, More
Join SI Premium – FREE
Depomed (NASDAQ: DEPO) reported Q2 EPS of $0.19, $0.03 better than the analyst estimate of $0.16. Revenue for the quarter came in at $63.3 million versus the consensus estimate of $63.8 million.
Guidance:
The Company is increasing its full-year adjusted EBITDA range to $145 million to $155 million from the previous range of $125 million to $135 million.
For earnings history and earnings-related data on Depomed (DEPO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rent the Runway (RENT) Reports Q2 Loss of $0.38/sh
- RH (RH) Tops Q2 EPS by $2.31
- Navan, Inc. (NAVN) Tops Q2 EPS by 1c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
